Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study

Michiel Vlaming, Eveline M A Bleiker, Inge M van Oort, Lambertus A L M Kiemeney, Margreet G E M Ausems, Michiel Vlaming, Eveline M A Bleiker, Inge M van Oort, Lambertus A L M Kiemeney, Margreet G E M Ausems

Abstract

Background: In international guidelines, germline genetic testing is recommended for patients with metastatic prostate cancer. Before undergoing germline genetic testing, these patients should receive pre-test counseling. In the standard genetic care pathway, pre-test counseling is provided by a healthcare professional of a genetics department. Because the number of patients with metastatic prostate cancer is large, the capacity in the genetics departments might be insufficient. Therefore, we aim to implement so-called mainstream genetic testing in the Netherlands for patients with metastatic prostate cancer. In a mainstream genetic testing pathway, non-genetic healthcare professionals discuss and order germline genetic testing. In our DISCOVER study, we will assess the experiences among patients and non-genetic healthcare professionals with this new pathway.

Methods: A multicenter prospective observational cohort study will be conducted in 15 hospitals, in different regions of the Netherlands. We developed an online training module on genetics in prostate cancer and the counseling of patients. After completion of this module, non-genetic healthcare professionals will provide pre-test counseling and order germline genetic testing in metastatic prostate cancer patients. Both non-genetic healthcare professionals and patients receive three questionnaires. We will determine the experience with mainstream genetic testing, based on satisfaction and acceptability. Patients with a pathogenic germline variant will also be interviewed. We will determine the efficacy of the mainstreaming pathway, based on time investment for non-genetic healthcare professionals and the prevalence of pathogenic germline variants.

Discussion: This study is intended to be one of the largest studies on mainstream genetic testing in prostate cancer. The results of this study can improve the mainstream genetic testing pathway in patients with prostate cancer.

Trial registration: The study is registered in the WHO's International Clinical Trials Registry Platform (ICTRP) under number NL9617.

Keywords: Genetic counseling; Germline genetic testing; Mainstream genetic testing; Prostate cancer.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Mainstreaming pathway for patients with metastatic prostate cancer in the Netherlands. ngHCP: non-genetic healthcare professional, dpt.: department
Fig. 2
Fig. 2
Study protocol for patients and non-genetic healthcare professionals

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
    1. National Cancer Institute (NCI): SEER Cancer Stat Facts: Prostate Cancer . Accessed March 10, 2022.
    1. Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate Cancer. Eur Urol. 2015;68(5):885–890. doi: 10.1016/j.eururo.2015.02.042.
    1. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;1:1–16. doi: 10.1200/PO.17.00029.
    1. Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, et al. Inherited mutations in men undergoing multigene panel testing for prostate Cancer: emerging implications for personalized prostate Cancer genetic evaluation. JCO Precis Oncol. 2017;1:1–17. 10.1200/PO.16.00039.
    1. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, et al. Clinical germline testing results of men with prostate Cancer: patient-level factors and implications of NCCN guideline expansion. JCO Precis Oncol. 2021;5:533–542. doi: 10.1200/PO.20.00432.
    1. Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate. 2018;78(5):401–407. doi: 10.1002/pros.23484.
    1. Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71(5):740–747. doi: 10.1016/j.eururo.2016.11.033.
    1. Nguyen-Dumont T, Dowty JG, MacInnis RJ, Steen JA, Riaz M, Dugué P-A, et al. Rare germline pathogenic variants identified by multigene panel testing and the risk of aggressive prostate cancer. Cancers. 2021;13(7):1495. doi: 10.3390/cancers13071495.
    1. Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, et al. Prevalence of germline variants in prostate Cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5(4):523–528. doi: 10.1001/jamaoncol.2018.6760.
    1. Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis. 2019;22(3):406–410. doi: 10.1038/s41391-018-0114-1.
    1. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate Cancer. N Engl J Med. 2016;375(5):443–453. doi: 10.1056/NEJMoa1603144.
    1. Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, et al. Pathogenic germline DNA repair gene and HOXB13 mutations in men with metastatic prostate cancer. JCO Precis Oncol. 2020;4:139–151. doi: 10.1200/PO.19.00284.
    1. Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate Cancer. J Clin Oncol. 2019;37(6):490–503. doi: 10.1200/jco.18.00358.
    1. Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, et al. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016;6(4):e010332. doi: 10.1136/bmjopen-2015-010332.
    1. Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210–216. doi: 10.1038/s41586-019-1689-y.
    1. Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228. doi: 10.1016/j.cell.2015.05.001.
    1. Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, et al. Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome. JCO Precis Oncol. 2019;3:1–12. doi: 10.1200/PO.19.00067.
    1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033.
    1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329. doi: 10.1200/JCO.2006.09.1066.
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–2416. doi: 10.1001/jama.2017.7112.
    1. Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4:CD002748. 10.1002/14651858.CD002748.pub4/full.
    1. Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660–669. doi: 10.1016/j.amjsurg.2016.06.010.
    1. Wood ME, McKinnon W, Garber J. Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. Breast J. 2020;26(8):1528–1534. doi: 10.1111/tbj.13969.
    1. Page EC, Bancroft EK, Brook MN, Assel M, Al Battat MH, Thomas S, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76(6):831–842. doi: 10.1016/j.eururo.2019.08.019.
    1. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811–1814. doi: 10.1093/jnci/djm203.
    1. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. doi: 10.1056/NEJMoa1911440.
    1. US Food Drug Administration: FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer . Accessed March 10, 2022.
    1. European Medicines Agency (EMA): Lynparza . Accessed March 10, 2022.
    1. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline part I. J Urol. 2021;205(1):14–21. doi: 10.1097/JU.0000000000001375.
    1. Mottet N, Cornford P, van den Bergh R, Briers E, De Santis M, Gillessen S, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG: guidelines on prostate Cancer. 2021.
    1. National Comprehensive Cancer Network: Prostate cancer (Version 2.2021)
    1. George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6(1):1–8. doi: 10.1038/srep29506.
    1. Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, et al. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian Cancer. J Clin Oncol. 2018;36(13):1300–1307. doi: 10.1200/JCO.2017.76.2781.
    1. Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, et al. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the north west of England. Eur J Hum Genet. 2020;28(11):1541–1547. doi: 10.1038/s41431-020-0692-y.
    1. Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, et al. The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients. Gynecol Oncol. 2020;158(2):431–439. doi: 10.1016/j.ygyno.2020.05.001.
    1. Grindedal EM, Jorgensen K, Olsson P, Gravdehaug B, Luras H, Schlichting E, et al. Mainstreamed genetic testing of breast cancer patients in two hospitals in south eastern Norway. Familial Cancer. 2020;19(2):133–142. doi: 10.1007/s10689-020-00160-x.
    1. Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, et al. Evaluation of Cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast Cancer. JAMA Netw Open. 2019;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    1. McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, et al. Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. Int J Gynecol Cancer. 2020;30(2):221–226. doi: 10.1136/ijgc-2019-000630.
    1. Powell CB, Laurent C, Ciaravino G, Garcia C, Han L, Hoodfar E, et al. Streamlining genetic testing for women with ovarian cancer in a northern California health care system. Gynecol Oncol. 2020;159(1):221–228. doi: 10.1016/j.ygyno.2020.07.027.
    1. Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, et al. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet. 2019;56(3):195–198. doi: 10.1136/jmedgenet-2017-105140.
    1. Richardson M, Min HJ, Hong Q, Compton K, Mung SW, Lohn Z, et al. Oncology clinic-based hereditary Cancer genetic testing in a population-based health care system. Cancers. 2020;12(2). 10.3390/cancers12020338.
    1. Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, et al. Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: a study of 255 patients and its impact on their management. Sci Rep. 2020;10(1):3390. doi: 10.1038/s41598-020-60149-5.
    1. Scott N, O'Sullivan J, Asgeirsson K, Macmillan D, Wilson E. Changing practice: moving to a specialist nurse-led service for BRCA gene testing. Br J Nurs. 2020;29(10):S6–S13. doi: 10.12968/bjon.2020.29.10.S6.
    1. Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, et al. Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes. J Med Genet. 2021;59. 10.1136/jmedgenet-2020-107416.
    1. Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, et al. Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genet Med. 2021:1–9. 10.1038/s41436-021-01262-2.
    1. Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, et al. Evaluation of a mainstream model of genetic testing for men with prostate Cancer. JCO Oncol Pract. 2021;17(2):e204–e216. doi: 10.1200/OP.20.00399.
    1. Bokkers K, Zweemer RP, Koudijs MJ, Stehouwer S, Velthuizen ME, Bleiker E, et al. Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer. Familial Cancer. 2021:1–10. 10.1007/s10689-021-00277-7.
    1. Bokkers K, Vlaming M, Engelhardt EG, Zweemer RP, van Oort IM, Kiemeney LA, et al. The feasibility of implementing mainstream germline genetic testing in routine Cancer care—a systematic review. Cancers. 2022;14(4):1059. doi: 10.3390/cancers14041059.
    1. Koedoot N, Molenaar S, Oosterveld P, Bakker P, de Graeff A, Nooy M, et al. The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns. 2001;45(3):187–193. doi: 10.1016/S0738-3991(01)00120-3.
    1. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Mak. 2003;23(4):281–292. doi: 10.1177/0272989X03256005.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82(10):1904–8. 10.1002/(SICI)1097-0142(19980515)82:;2-X.
    1. Eijzenga W, Bleiker EM, Hahn DE, Kluijt I, Sidharta GN, Gundy C, et al. Psychosocial aspects of hereditary cancer (PAHC) questionnaire: development and testing of a screening questionnaire for use in clinical cancer genetics. Psychooncology. 2014;23(8):862–869. doi: 10.1002/pon.3485.
    1. Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A. 2003;116(1):11–19. doi: 10.1002/ajmg.a.10868.
    1. de Geus E, Aalfs CM, Menko FH, Sijmons RH, Verdam MG, de Haes HC, et al. Development of the informing relatives inventory (IRI): assessing index patients’ knowledge, motivation and self-efficacy regarding the disclosure of hereditary Cancer risk information to relatives. Int J Behav Med. 2015;22(4):551–560. doi: 10.1007/s12529-014-9455-x.
    1. Castro E, Goh C, Olmos D. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748. doi: 10.1200/JCO.2012.43.1882.
    1. Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of Cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8(6):871–8. 10.1001/jamaoncol.2022.0476.
    1. Douma KF, Smets EM, Allain DC. Non-genetic health professionals’ attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer. Familial Cancer. 2016;15(2):341–350. doi: 10.1007/s10689-015-9852-6.
    1. Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, et al. Knowledge and practice regarding prostate cancer germline testing among urologists: gaps to address for optimal implementation✰,✰✰. Cancer Treat Res Commun. 2020;25:100212. doi: 10.1016/j.ctarc.2020.100212.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit